<DOC>
	<DOCNO>NCT00977288</DOCNO>
	<brief_summary>This study investigate effect MK0859 administer alone combination atorvastatin lower Low Density Lipoprotein -Cholesterol ( LDL-C ) Japanese patient dyslipidemia .</brief_summary>
	<brief_title>A Study Safety Efficacy MK0859 ( Anacetrapib ) Japanese Patients With Dyslipidemia ( 0859-029 )</brief_title>
	<detailed_description>This dose range study evaluate efficacy safety MK-0859 Japanese patient . Eligible patient assign 1 10 treatment group ( include treatment group without administrative atorvastatin ) 8-week treatment period follow 8-week reversibility period . As additional follow-up , pregnancy information woman childbearing potential treat MK-0859 study collect retrospectively period 4 year last dose MK-0859 .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Patient male female age 20 75 year diagnose dyslipidemia Patients Coronary Heart Disease ( CHD ) CHDequivalent disease ( except diabetes ) Patients uncontrolled diabetes Patient currently participate participate study investigational compound within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>